1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65F810FC8E8D66A6485257D0F005FC3D6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/5F810FC8E8D66A6485257D0F005FC3D6!OpenDocument
18
19OpenDocument
203.227.249.234
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services ╗ Medical AffairsThought Leader Services

Effective Thought Leader Management: Interaction Tactics and Challenges

ID: 5316


Features:

10 Info Graphics

13 Data Graphics

140+ Metrics

3 Narratives


Pages/Slides: 31


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Effective Thought Leader Management: Interaction Tactics and Challenges"


STUDY OVERVIEW

As the healthcare landscape evolves, the role of Medical Affairs functions within pharma organizations has become increasingly important. Among the many responsibilities of medical affairs groups, thought leader management is considered critical because companies look to thought leaders to inform and guide clinical programs.

Best Practices, LLC performed this research study to better understand thought leader interaction frequency and channels. The research also explores challenges and critical strategies to mitigate the negative effects of a changing regulatory landscape.

The benchmark data in this study will help companies find better ways to create effective thought leader management strategies that will enhance and inform a critical aspect of an organization’s operations.

This document includes mature and emerging markets segment analysis.

KEY TOPICS

  • Benchmark Participant Demographics
  • Interaction Frequency & Channel
  • Thought Leader Access Challenges
  • Challenges in Interactions

SAMPLE KEY METRICS
  • Frequency of contact with National and Regional thought leaders in mature markets
  • Frequency of contact with National and Regional thought leaders in emerging markets
  • Annual interaction with thought leaders in mature markets
  • Annual interaction with thought leaders in emerging markets
  • Face-to-Face visits per year in mature markets
  • Face-to-Face visits per year in emerging markets
  • Thought leader access challenges in mature markets
  • Thought leader access challenges in emerging markets
  • Level of interactions with health care payers & providers in mature markets
  • Level of interactions with health care payers & providers in mature markets

SAMPLE KEY FINDING
  • Frequency of Contact with Regional TLs:áBoth mature market and emerging market companies contact regional TLs less than they contact national TLs. On average, mature market companies contact regional TLs 26 times per year, and emerging markets companies contact regional TLs 30 times a year.
  • Relationship Challenges: Within mature market segment companies top threats to interactions with thought leaders are increasing regulatory barriers and internal changes among TLs / institutions in how they approach industry. Emerging market segment companies are expecting similar challenges in interactions with thought leaders. However, in addition to the barriers related to thought leaders or their home institutions, shrinking medical affairs budgets will impact emerging markets.
METHODOLOGY

Forty survey responses from Medical Affairs leaders at 32 pharmaceutical and medical device companies in the mature market and emerging markets. This study includes segment perspectives for both mature and emerging markets.

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Chemical; Manufacturing; Medical Device; Consumer Products; Diagnostic; Technology


Companies Profiled:
Sanofi; Shire; Astellas; AstraZeneca; Genentech; Dr Reddy's Laboratories; Biogen; Merck; Eli Lilly; Teva Pharmaceutical Industries Ltd; Biocon; United Therapeutics; Amgen; Baxter Healthcare; Acorda Therapeutics; Upsher-Smith; Crescendo Bioscience; ProStrakan; Cubist Pharmaceuticals; Pierre Fabre Medicament; Ironwood; Kadmon Pharmaceuticals; Covidien; Roche; Medtronic; GE Healthcare; Bayer Healthcare; BARD; BD

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.